

=> fil hcap

FILE 'HCAPLUS' ENTERED AT 16:56:38 ON 14 JUN 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 14 Jun 2007 VOL 146 ISS 25


FILE LAST UPDATED: 13 Jun 2007 (20070613/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d que 14

L1 STR



VAR G1=C/N

REP G2=(0-3). C

VAR G3=N/O/S

NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 29

STEREO ATTRIBUTES: NONE

L3 105 SEA FILE=REGISTRY SSS FUL L1

L4 3 SEA FILE=HCAPLUS ABB=ON PLU=ON L3

=> d 14 ibib abs hitstr tot

L4 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:326378 HCAPLUS Full-text

DOCUMENT NUMBER: 145:24086

TITLE: Mechanistic basis for the action of new cephalosporin antibiotics effective against methicillin- and vancomycin-resistant *Staphylococcus aureus*.

AUTHOR(S): Fuda, Cosimo; Heseck, Dusan; Lee, Mijoon; Heilmayer, Werner; Novak, Rodger; Vakulenko, Sergei B.; Mobashery, Shahriar

CORPORATE SOURCE: Department of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, IN, 46556, USA

SOURCE: Journal of Biological Chemistry (2006), 281(15), 10035-10041

CODEN: JBCHA3; ISSN: 0021-9258

PUBLISHER: American Society for Biochemistry and Molecular Biology

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Emergence of methicillin-resistant *Staphylococcus aureus* (MRSA) has created challenges in treatment of nosocomial infections. The recent clin. emergence of vancomycin-resistant MRSA is a new disconcerting chapter in the evolution of these strains. *S. aureus* normally produces four PBPs, which are susceptible to modification by β -lactam antibiotics, an event that leads to bacterial death. The gene product of *mecA* from MRSA is a penicillin-binding protein (PBP) designated PBP 2a. PBP 2a is refractory to the action of all com. available β -lactam antibiotics. Furthermore, PBP 2a is capable of taking over the functions of the other PBPs of *S. aureus* in the face of the challenge by β -lactam antibiotics. Three cephalosporins (compds. 1-3) have been studied herein, which show antibacterial activities against MRSA, including the clin. important vancomycin-resistant strains. These cephalosporins exhibit substantially smaller dissociation consts. for the preacylation complex compared with the case of typical cephalosporins, but their pseudo-second-order rate consts. for encounter with PBP 2a (k_2/K_s) are not very large ($\leq 200 \text{ M}^{-1} \text{ s}^{-1}$). It is documented herein that these cephalosporins facilitate a conformational change in PBP 2a, a process that is enhanced in the presence of a synthetic surrogate for cell wall, resulting in increases in the k_2/K_s parameter and in more facile enzyme inhibition. These findings argue that the novel cephalosporins are able to co-opt interactions between PBP 2a and the cell wall in gaining access to the active site in the inhibition process, a set of events that leads to effective inhibition of PBP 2a and the attendant killing of the MRSA strains.

IT 650590-51-5, ABRI 2901


RL: BSU (Biological study, unclassified); BIOL (Biological study)
(mechanistic basis for action of new cephalosporin antibiotics effective against methicillin- and vancomycin-resistant *Staphylococcus aureus*)

RN 650590-51-5 HCAPLUS

CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,
3-[(E)-[[[(trans-4-aminocyclohexyl)amino]iminomethyl]methylhydrazono]methyl]-7-[[[(2Z)-(5-amino-1,2,4-thiadiazol-3-yl)[(fluoromethoxy)imino]acetyl]amino]-8-oxo-, trihydrochloride, (6R,7R)-(9CI). (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



REFERENCE COUNT: 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 3 HCAPLUS. COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2004:648529 HCAPLUS Full-text
 DOCUMENT NUMBER: 141:190629
 TITLE: Preparation of cephalosporin ester derivatives for use in pharmaceutical compositions for the treatment of microbial infections
 INVENTOR(S): Ascher, Gerd; Thirring, Klaus
 PATENT ASSIGNEE(S): Sandoz GmbH, Austria; Sandoz AG
 SOURCE: PCT Int. Appl., 42 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004067536	A2	20040812	WO 2004-EP683	20040127
WO 2004067536	A3	20041223		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI				
CA 2509793	A1	20040812	CA 2004-2509793	20040127
EP 1590354	A2	20051102	EP 2004-705412	20040127
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2004007073	A	20060124	BR 2004-7073	20040127
CN 1745086	A	20060308	CN 2004-80003021	20040127
JP 2006515633	T	20060601	JP 2006-501619	20040127
US 2006122164	A1	20060608	US 2005-541017	20050628
PRIORITY APPLN. INFO.:				
			GB 2003-1938	A 20030128
			WO 2004-EP683	W 20040127
OTHER SOURCE(S): MARPAT 141:190629				
GI				



AB Cephalosporin esters, such as I [R = substituted alkyl ester group; X = substituted hydrazono, guanidino, or semicarbazido group], were prepared for therapeutic use as antibiotics and may be used in combination with an immunosuppressant, immunomodulator, or anti-inflammatory agent. Thus, cephalosporin ester II [R = -CH(Me)OC(O)OCH₂CH(OH)CH₂OH] was prepared via a series of synthetic steps which included ester formation of the corresponding 3-formyl substituted acid sodium salt I (R = Na, X = O) with carbonic acid diester MeCH(I)OC(O)OCH₂CH(OR₁)CH₂OR₂ (R₁R₂ = CMe₂), followed by reaction of the cyclic-diprotected diol ester with 1-piperazinecarboximidic acid, 1-methylhydrazide using 2N HCl to install the desired hydrazono group, and finally, deprotection of the diol functionality in the ester moiety again using HCl to form the target cephalosporin ester. Appropriate dosages and pharmaceutical formulation of the prepared esters were discussed.

IT 650590-51-5P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of cephalosporin ester β -lactam antibiotics for use in pharmaceutical compns. for the treatment of microbial infections)

RN 650590-51-5 HCAPLUS

CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 3-[(E)-[[[(trans-4-aminocyclohexyl)amino]iminomethyl]methylhydrazono]methyl]-7-[[[(2Z)-(5-amino-1,2,4-thiadiazol-3-yl)[(fluoromethoxy)imino]acetyl]amino]-8-oxo-, trihydrochloride, (6R,7R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



● 3 HCl

IT 648908-95-6P 737805-19-5P 737805-20-8P


RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of cephalosporin ester β -lactam antibiotics for use in pharmaceutical compns. for the treatment of microbial infections)

RN 648908-95-6 HCAPLUS

CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,
3-[(E)-[[[(trans-4-aminocyclohexyl)amino]iminomethyl]methylhydrazono]methyl]-7-[[[(2Z)-(5-amino-1,2,4-thiadiazol-3-yl)][(fluoromethoxy)imino]acetyl]amino]-8-oxo-, (6R,7R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 737805-19-5 HCAPLUS

CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,
3-[[[[(4-aminocyclohexyl)amino]iminomethyl]methylhydrazono]methyl]-7-[[[(2Z)-(5-amino-1,2,4-thiadiazol-3-yl)][(fluoromethoxy)imino]acetyl]amino]-8-oxo-, 1-[[[(9H-fluoren-9-ylmethoxy)carbonyl]oxy]ethyl ester, (6R,7R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as described by E or Z.




RN 737805-20-8 HCAPLUS

CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,
3-[[[(4-aminocyclohexyl)amino]iminomethyl]methylhydrazono]methyl]-7-
[[{(2Z)-(5-amino-1,2,4-thiadiazol-3-yl)[(fluoromethoxy)imino]acetyl]amino]-
8-oxo-, 1-[[{(2,3-dihydroxypropoxy)carbonyl]oxy]ethyl ester, (6R,7R)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as described by E or Z.



L4 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:60517 HCAPLUS Full-text

DOCUMENT NUMBER: 140:128191

TITLE: Preparation of acylamino(methylhydrazono)methylcephalo-
sporin derivatives for the treatment of microbial
diseases

INVENTOR(S): Ascher, Gerd; Heilmayer, Werner; Schranz, Michael;
Wieser, Josef

PATENT ASSIGNEE(S): Sandoz GmbH, Austria

SOURCE: PCT Int. Appl., 55 pp.

This case

DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004007505	A1	20040122	WO 2003-EP7603	20030714
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SE, SG, SK, SY, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW				
RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR				
CA 2492373	A1	20040122	CA 2003-2492373	20030714
AU 2003250056	A1	20040202	AU 2003-250056	20030714
BR 2003012698	A	20050503	BR 2003-12698	20030714
EP 1529050	A1	20050511	EP 2003-763841	20030714
EP 1529050	B1	20060524		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1678616	A	20051005	CN 2003-819975	20030714
JP 2005536499	T	20051202	JP 2004-520619	20030714
AT 327239	T	20060615	AT 2003-763841	20030714
IN 2004CN03075	A	20060217	IN 2004-CN3075	20041231
NO 2005000781	A	20050214	NO 2005-781	20050214
US 2005234233	A1	20051020	US 2005-527882	20050315
HK 1077299	A1	20070323	HK 2005-109278	20051020
PRIORITY APPLN. INFO.:				
			GB 2002-16418	A 20020715
			GB 2002-22177	A 20020924
			GB 2002-23974	A 20021015
			GB 2002-23975	A 20021015
			GB 2002-23976	A 20021015
			GB 2002-23977	A 20021015
			WO 2003-EP7603	W 20030714

OTHER SOURCE(S): MARPAT 140:128191
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The present invention discloses preparation of acylamino(methylhydrazono)methyl cephalosporin derivs., such as I or II [W = CH, N; R1 = OH, alkoxy; R2 = H, ester; R3 = H, alkyl, alkenyl, cycloalkyl; R4 = H, alkyl; A = cyclohexyl, phenyl; R5, R6 = H, alkyl, alkenyl, arylcarbonyl, alkylcarbonyl, heterocyclalkylcarbonyl; X = NH, O, S, alkylamino, cycloalkylamino; R8 = alkyl; Y = O, S; m, n = 0-1], for their therapeutic use as antimicrobial agents. Thus, cephalosporin trans-diaminocyclohexane derivative III.HCl is prepared via a multistep synthetic sequence starting from S-methyl-2-methyl-isothiosemicarbazide hydrochloride, trans-1,4-diaminocyclohexane and N-(1,4,5a,6-tetrahydro-3-hydroxy-1,7-dioxo-3H,7H-azeto(2,1-b)furo(3,4-d)(1,3)thiazin-6-yl)-2-(5-amino-1,2,4-thiadiazol-3-yl)-(Z)-2-fluoromethoxyiminoacetic acid amide.

IT 648906-72-3P 648906-73-4P 648906-74-5P

648906-75-6P 648906-76-7P 648906-77-8P
 648906-78-9P 648906-79-0P 648906-80-3P
 648908-95-6P 650589-68-7P 650589-70-1P
 650589-72-3P 650589-74-5P 650589-76-7P
 650589-78-9P 650589-80-3P 650589-82-5P
 650589-84-7P 650589-86-9P 650589-88-1P
 650589-90-5P 650589-92-7P 650589-95-0P
 650589-97-2P 650589-99-4P 650590-01-5P
 650590-03-7P 650590-05-9P 650590-07-1P
 650590-09-3P 650590-11-7P 650590-13-9P
 650590-15-1P 650590-17-3P 650590-19-5P
 650590-21-9P 650590-23-1P 650590-25-3P
 650590-27-5P 650590-29-7P 650590-31-1P
 650590-33-3P 650590-35-5P 650590-37-7P
 650590-39-9P 650590-41-3P 650590-43-5P
 650590-45-7P 650590-47-9P 650590-49-1P
 650590-53-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of acylamino(methylhydrazono)methylcephalosporin derivs. as antimicrobial agents and their intermediates)

RN 648906-72-3 HCAPLUS

CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 3-[(E)-[[[(2-aminocyclohexyl)amino]iminomethyl]hydrazono]methyl]-7-[[[(2Z)-(5-amino-1,2,4-thiadiazol-3-yl)[(fluoromethoxy)imino]acetyl]amino]-8-oxo-, monohydrochloride, (6R,7R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




● HCl

RN 648906-73-4 HCAPLUS

CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 3-[(E)-[[[(2-aminocyclohexyl)amino] (methylamino)methylene]hydrazono]methyl]-7-[[[(2Z)-(5-amino-1,2,4-thiadiazol-3-yl)[(fluoromethoxy)imino]acetyl]amino]-8-oxo-, monohydrochloride, (6R,7R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 648906-74-5 HCAPLUS

CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,
3-[(E)-[[[(3-aminocyclohexyl)amino]iminomethyl]methylhydrazono]methyl]-7-
[[[(2Z)-(5-amino-1,2,4-thiadiazol-3-yl)[(fluoromethoxy)imino]acetyl]amino]-
8-oxo-, monohydrochloride, (6R,7R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 648906-75-6 HCAPLUS

CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,
3-[(E)-[[[[[3-(aminomethyl)cyclohexyl]methyl]amino]iminomethyl]methylhydra-
zono]methyl]-7-[[[(2Z)-(5-amino-1,2,4-thiadiazol-3-
yl)[(fluoromethoxy)imino]acetyl]amino]-8-oxo-, monohydrochloride, (6R,7R)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.

PAGE 1-A




PAGE 1-B

—NH₂

RN 648906-76-7 HCAPLUS
 CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,
 3-[(E)-[[[[[3-(aminomethyl)cyclohexyl]methyl]amino](methylimino)methyl]met
 hylhydrazono]methyl]-7-[[[(2Z)-(5-amino-1,2,4-thiadiazol-3-
 yl)[(fluoromethoxy)imino]acetyl]amino]-8-oxo-, monohydrochloride, (6R,7R)-
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.

PAGE 1-A




PAGE 1-B

—NH₂

RN 648906-77-8 HCAPLUS
 CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,
 3-[(E)-[[[(3-aminophenyl)methyl]amino]iminomethyl]methylhydrazono]methyl]-
 7-[(2Z)-(5-amino-1,2,4-thiadiazol-3-yl)] [(fluoromethoxy)imino]acetyl]amino
]-8-oxo-, monohydrochloride, (6R,7R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.

PAGE 1-A




PAGE 1-B

—NH₂

RN 648906-78-9 HCAPLUS
 CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,
 3-[(E)-[[[3-(aminomethyl)phenyl]methyl]amino]iminomethyl]methylhydrazono
]methyl]-7-[[[(2Z)-(5-amino-1,2,4-thiadiazol-3-
 yl)[(fluoromethoxy)imino]acetyl]amino]-8-oxo-, monohydrochloride, (6R,7R)-
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.

PAGE 1-A



PAGE 1-B

—NH₂


RN 648906-79-0 HCAPLUS

CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,
 3-[(E)-[[[4-(aminomethyl)phenyl]methyl]amino]iminomethyl]methylhydrazono
]methyl]-7-[[[(2Z)-(5-amino-1,2,4-thiadiazol-3-yl)][(fluoromethoxy)imino]acetyl]amino]-8-oxo-, monohydrochloride, (6R,7R)-
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.

PAGE 1-A




PAGE 1-B

NH₂

RN 648906-80-3 HCAPLUS
 CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,
 3-[(E)-[[[[[4-(aminomethyl)phenyl]methyl]amino]iminomethyl]methylhydrazono
]methyl]-7-[[[(2Z)-(5-amino-1,2,4-thiadiazol-3-yl)(hydroxyimino)acetyl]amino]-8-oxo-, monohydrochloride, (6R,7R)-(9CI)
 (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 648908-95-6 HCAPLUS

CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,
3-[(E)-[[[(trans-4-aminocyclohexyl)amino]iminomethyl]methylhydrazono]methyl]-7-[[[(2Z)-(5-amino-1,2,4-thiadiazol-3-yl)[(fluoromethoxy)imino]acetyl]amino]-8-oxo-, (6R,7R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 650589-68-7 HCAPLUS

CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,
3-[(E)-[[[(trans-4-aminocyclohexyl)amino]iminomethyl]methylhydrazono]methyl]-7-[[[(2Z)-(5-amino-1,2,4-thiadiazol-3-yl)[(fluoromethoxy)imino]acetyl]amino]-8-oxo-, monohydrochloride, (6R,7R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 650589-70-1 HCAPLUS

CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,
3-[(E)-[[[(cis-4-aminocyclohexyl)amino]iminomethyl]methylhydrazono]methyl]-
7-[[[(2Z)-(5-amino-1,2,4-thiadiazol-3-yl)][(fluoromethoxy)imino]acetyl]amino
]-8-oxo-, monohydrochloride, (6R,7R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry:

Double bond geometry as shown.




RN 650589-72-3 HCAPLUS

CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,
3-[(E)-[[[(trans-4-aminocyclohexyl)amino]iminomethyl]ethylhydrazono]methyl
]-7-[[[(2Z)-(5-amino-1,2,4-thiadiazol-3-yl)][(fluoromethoxy)imino]acetyl]ami
no]-8-oxo-, monohydrochloride, (6R,7R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry:

Double bond geometry as shown.




RN 650589-74-5 HCAPLUS

CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,
3-[(E)-[[[(trans-4-aminocyclohexyl)amino]iminomethyl]methylhydrazono]methyl]-7-[[[(2Z)-(2-amino-4-thiazolyl)(hydroxyimino)acetyl]amino]-8-oxo-,
monohydrochloride, (6R,7R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 650589-76-7 HCAPLUS

CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,
3-[(E)-[[[(trans-4-aminocyclohexyl)amino]iminomethyl]methylhydrazono]methyl]-7-[[[(2Z)-(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-8-oxo-,
monohydrochloride, (6R,7R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 650589-78-9 HCAPLUS

CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,
3-[(E)-[[[(trans-4-aminocyclohexyl)amino]iminomethyl]-2-propenylhydrazone]methyl]-7-[[[(2Z)-(5-amino-1,2,4-thiadiazol-3-yl)[(fluoromethoxy)imino]acetyl]amino]-8-oxo-, monohydrochloride, (6R,7R)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 650589-80-3 HCAPLUS

CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,
3-[(E)-[[[(trans-4-aminocyclohexyl)amino]iminomethyl]hydrazone]methyl]-7-[[[(2Z)-(5-amino-1,2,4-thiadiazol-3-yl)[(fluoromethoxy)imino]acetyl]amino]-8-oxo-, monohydrochloride, (6R,7R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 650589-82-5 HCAPLUS

CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,
7-[[[(2Z)-(5-amino-1,2,4-thiadiazol-3-yl)][(fluoromethoxy)imino]acetyl]amino]
]-3-[(E)-[[[trans-4-(dimethylamino)cyclohexyl]amino]iminomethyl]hydrazono]
]methyl]-8-oxo-, monohydrochloride, (6R,7R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 650589-84-7 HCAPLUS

CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,
7-[[[(2Z)-(5-amino-1,2,4-thiadiazol-3-yl)][(fluoromethoxy)imino]acetyl]amino]
]-3-[(E)-[[[trans-4-(dimethylamino)cyclohexyl]amino]iminomethyl]methylhydrazono]
]methyl]-8-oxo-, monohydrochloride, (6R,7R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 650589-86-9 HCAPLUS


CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 3-[(E)-[[[trans-4-[(4-aminophenyl)sulfonyl]amino]cyclohexyl]amino]iminomethyl]methylhydrazono]methyl]-7-[[[(2Z)-(5-amino-1,2,4-thiadiazol-3-yl)][(fluoromethoxy)imino]acetyl]amino]-8-oxo-, monohydrochloride, (6R,7R)-(9CI) (CA INDEX NAME).

Absolute stereochemistry.
Double bond geometry as shown.




PAGE 1-A

PAGE 1-B




RN 650589-88-1 HCAPLUS
 CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,
 7-[[[(2Z)-(5-amino-1,2,4-thiadiazol-3-yl)][(fluoromethoxy)imino]acetyl]amino
]-3-[(E)-[(methylamino)methyl[trans-4-(methylamino)cyclohexyl]amino]meth
 ylene]hydrazono]methyl]-8-oxo-, monohydrochloride, (6R,7R)-(9CI) (CA
 INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 650589-90-5 HCAPLUS
 CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,
 3-[(E)-[[[(trans-4-aminocyclohexyl)amino](methylamino)methylene]hydrazono]
 methyl]-7-[[[(2Z)-(5-amino-1,2,4-thiadiazol-3-yl)][(fluoromethoxy)imino]acet
 yl]amino]-8-oxo-, monohydrochloride, (6R,7R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 650589-92-7 HCAPLUS
 CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,
 7-[[[(2Z)-(5-amino-1,2,4-thiadiazol-3-yl)][(fluoromethoxy)imino]acetyl]amino
]-3-[(E)-[[[trans-4-(dimethylamino)cyclohexyl]amino](methylamino)methylen


10/527,882

June 14, 2007

e]hydrazono]methyl]-8-oxo-, monohydrochloride, (6R,7R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




● HCl

RN 650589-95-0 HCAPLUS

CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 3-[(E)-[[[(trans-4-aminocyclohexyl)amino]iminomethyl]methylhydrazono]methyl]-7-[[[(2Z)-(2-amino-4-thiazolyl)][(1-carboxy-1-methylethoxy)imino]acetyl]amino]-8-oxo-, monohydrochloride, (6R,7R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




● HCl

PAGE 1-A

NH₂


RN 650589-97-2 HCAPLUS
 CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,
 3-[(E)-[[[(trans-4-aminocyclohexyl)amino]thioxomethyl]methylhydrazono]meth
 yl]-7-[[[(2Z)-(5-amino-1,2,4-thiadiazol-3-yl)[(fluoromethoxy)imino]acetyl]a
 mino]-8-oxo-, monohydrochloride, (6R,7R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 650589-99-4 HCAPLUS
 CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,
 3-[(E)-[[[(trans-4-aminocyclohexyl)amino]carbonyl]methylhydrazono]methyl]-
 7-[[[(2Z)-(5-amino-1,2,4-thiadiazol-3-yl)[(fluoromethoxy)imino]acetyl]amino
]-8-oxo-, monohydrochloride, (6R,7R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 650590-01-5 HCAPLUS

CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,
3-[(E)-[[[(trans-4-aminocyclohexyl)amino] (methylimino)methyl]methylhydrazono]methyl]-7-[[{(2Z)-(5-amino-1,2,4-thiadiazol-3-yl) [(fluoromethoxy)imino]acetyl]amino]-8-oxo-, monohydrochloride, (6R,7R)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 650590-03-7 HCAPLUS

CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,
3-[(E)-[[[(trans-4-aminocyclohexyl)amino] iminomethyl]cyclopropylhydrazono]methyl]-7-[[{(2Z)-(5-amino-1,2,4-thiadiazol-3-yl) [(fluoromethoxy)imino]acetyl]amino]-8-oxo-, monohydrochloride, (6R,7R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 650590-05-9 HCAPLUS

CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,
3-[(E)-[[[(cis-4-aminocyclohexyl)methylamino](methylamino)methylene]hydrazono]methyl]-7-[[[(2Z)-(5-amino-1,2,4-thiadiazol-3-yl)][(fluoromethoxy)imino]acetyl]amino]-8-oxo-, monohydrochloride, (6R,7R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 650590-07-1 HCAPLUS

CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,
3-[(E)-[[[(trans-4-aminocyclohexyl)methylamino](methylamino)methylene]hydrazono]methyl]-7-[[[(2Z)-(5-amino-1,2,4-thiadiazol-3-yl)][(fluoromethoxy)imino]acetyl]amino]-8-oxo-, monohydrochloride, (6R,7R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




● HCl

RN 650590-09-3 HCAPLUS

CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,
 3-[(E)-[[[(cis-4-aminocyclohexyl)methylamino](methylimino)methyl]methylhydrazono]methyl]-7-[(2Z)-(5-amino-1,2,4-thiadiazol-3-yl)][(fluoromethoxy)imino]acetyl]amino]-8-oxo-, monohydrochloride, (6R,7R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as described by E or Z.



● HCl


RN 650590-11-7 HCAPLUS

CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,
 7-[(2Z)-(5-amino-1,2,4-thiadiazol-3-yl)][(fluoromethoxy)imino]acetyl]amino]-3-[(E)-[[imino[[trans-4-(2-propenylamino)cyclohexyl]amino]methyl]methylhydrazono]methyl]-8-oxo-, monohydrochloride, (6R,7R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 650590-13-9 HCAPLUS
 CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,
 7-[[[(2Z)-(5-amino-1,2,4-thiadiazol-3-yl)] [(fluoromethoxy)imino]acetyl]amino]
]-3-[(E)-[[[trans-4-(di-2-propenylamino)cyclohexyl]amino]iminomethyl]meth
 ylhydrazono]methyl]-8-oxo-, monohydrochloride, (6R,7R)-(9CI) (CA INDEX
 NAME)

Absolute stereochemistry.
 Double bond geometry as shown.

PAGE 1-A




PAGE 1-B



RN 650590-15-1 HCAPLUS
 CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,
 7-[[[(2Z)-(5-amino-1,2,4-thiadiazol-3-yl)[(fluoromethoxy)imino]acetyl]amino]
]-3-[(E)-[methyl[[[trans-4-[(1-methylethyl)amino]cyclohexyl]amino][(1-
 methylethyl)imino]methyl]hydrazono]methyl]-8-oxo-, monohydrochloride,
 (6R,7R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.

PAGE 1-A




PAGE 1-B

NHPr-i

RN 650590-17-3 HCAPLUS
 CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,
 7-[[[(2Z)-(5-amino-1,2,4-thiadiazol-3-yl)[(fluoromethoxy)imino]acetyl]amino]
]-3-[(E)-[[[imino[[trans-4-[(1-methylethyl)amino]cyclohexyl]amino]methyl]me
 thylhydrazono]methyl]-8-oxo-, monohydrochloride, (6R,7R)- (9CI) (CA INDEX
 NAME)

Absolute stereochemistry.
 Double bond geometry as shown.

PAGE 1-A




PAGE 1-B

NHPr-i

RN 650590-19-5 HCAPLUS
 CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,
 7-[[[(2Z)-(5-amino-1,2,4-thiadiazol-3-yl)[(fluoromethoxy)imino]acetyl]amino]
]-3-[(E)-[[[trans-4-(ethylamino)cyclohexyl]amino]iminomethyl]methylhydraz
 ono]methyl]-8-oxo-, monohydrochloride, (6R,7R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 650590-21-9 HCAPLUS

CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,
7-[[[(2Z)-(5-amino-1,2,4-thiadiazol-3-yl)][(fluoromethoxy)imino]acetyl]amino]
]-3-[(E)-[[[trans-4-(diethylamino)cyclohexyl]amino]iminomethyl]methylhydr
azono]methyl]-8-oxo-, monohydrochloride, (6R,7R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 650590-23-1 HCAPLUS

CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,
7-[[[(2Z)-(5-amino-1,2,4-thiadiazol-3-yl)][(fluoromethoxy)imino]acetyl]amino]
]-3-[(E)-[[[imino[[trans-4-(propylamino)cyclohexyl]amino]methyl]methylhydr
azono]methyl]-8-oxo-, monohydrochloride, (6R,7R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B


NHPr-n

RN 650590-25-3 HCAPLUS

CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,
 7-[[[(2Z)-(5-amino-1,2,4-thiadiazol-3-yl)][(fluoromethoxy)imino]acetyl]amino
]-3-[(E)-[[[trans-4-(dipropylamino)cyclohexyl]amino]iminomethyl]methylhyd
 razono]methyl]-8-oxo-, monohydrochloride, (6R,7R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.

PAGE 1-A




PAGE 1-B

...N(Pr-n)₂

RN 650590-27-5 HCAPLUS
 CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,
 7-[[[(2Z)-(5-amino-1,2,4-thiadiazol-3-yl) [(fluoromethoxy) imino] acetyl] amino
]-3-[[[E)-[[imino[[trans-4-(methylamino) cyclohexyl] amino] methyl] methylhydra
 zono] methyl]-8-oxo-, monohydrochloride, (6R,7R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



• HCl

RN 650590-29-7 HCAPLUS
 CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,
 3-[[[E)-[[[(trans-4-aminocyclohexyl) methylamino] iminomethyl] hydrazono] methyl
]-7-[[[(2Z)-(5-amino-1,2,4-thiadiazol-3-yl) [(fluoromethoxy) imino] acetyl] am
 ino]-8-oxo-, monohydrochloride, (6R,7R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 650590-31-1 HCAPLUS

CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,
3-[(E)-[[[(trans-4-aminocyclohexyl)methylamino]iminomethyl]methylhydrazono
methyl]-7-[(2Z)-(5-amino-1,2,4-thiadiazol-3-
yl)[(fluoromethoxy)imino]acetyl]amino]-8-oxo-, monohydrochloride, (6R,7R)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 650590-33-3 HCAPLUS

CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,
3-[(E)-[[[[trans-4-(acetylamino)cyclohexyl]amino]iminomethyl]methylhydrazo
no]methyl]-7-[(2Z)-(5-amino-1,2,4-thiadiazol-3-
yl)[(fluoromethoxy)imino]acetyl]amino]-8-oxo-, dihydrochloride, (6R,7R)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 650590-35-5 HCAPLUS

CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,
 7-[[[(2Z)-(5-amino-1,2,4-thiadiazol-3-yl)[(fluoromethoxy)imino]acetyl]amino]
]-3-[(E)-[[[trans-4-(benzoylamino)cyclohexyl]amino]iminomethyl]methylhydr
 azono]methyl]-8-oxo-, monohydrochloride, (6R,7R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.

PAGE 1-A




PAGE 1-B


Ph

RN 650590-37-7 HCAPLUS
 CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,
 3-[(E)-[[[trans-4-[[2-(acetyloxy)benzoyl]amino]cyclohexyl]amino]iminometh
 yl]methylhydrazono]methyl]-7-[[[(2Z)-(5-amino-1,2,4-thiadiazol-3-
 yl)](fluoromethoxy)imino]acetyl]amino]-8-oxo-, monohydrochloride, (6R,7R)-
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




PAGE 1-B



RN 650590-39-9 HCAPLUS
 CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,
 7-[[[(2Z)-(5-amino-1,2,4-thiadiazol-3-yl)](fluoromethoxy)imino]acetyl]amino
]-3-[(E)-[[imino[[trans-4-[(phenoxyacetyl)amino]cyclohexyl]amino]methyl]me
 thylhydrazono]methyl]-8-oxo-, monohydrochloride, (6R,7R)- (9CI) (CA INDEX
 NAME)

Absolute stereochemistry.
 Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 650590-41-3 HCAPLUS

CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,
 3-[(E)-[[[trans-4-[[4-(acetylamino)phenyl]sulfonyl]amino]cyclohexyl]amino]iminomethyl]methylhydrazono]methyl]-7-[[2Z)-(5-amino-1,2,4-thiadiazol-3-yl)[(fluoromethoxy)imino]acetyl]amino]-8-oxo-, monohydrochloride, (6R,7R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 650590-43-5 HCAPLUS

CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,
 7-[[[(2Z)-(5-amino-1,2,4-thiadiazol-3-yl)[(fluoromethoxy)imino]acetyl]amino]
]-3-[(E)-[[imino[[trans-4-[(2-thienylacetyl)amino]cyclohexyl]amino]methyl]
 methylhydrazono]methyl]-8-oxo-, monohydrochloride, (6R,7R)-(9CI) (CA
 INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

PAGE 1-A



● HCl

PAGE 1-B




RN 650590-45-7 HCAPLUS

CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,
 3-[(E)-[[[(trans-4-aminocyclohexyl)imino](methylthio)methyl]methylhydrazono]
 methyl]-7-[[[(2Z)-(5-amino-1,2,4-thiadiazol-3-

yl) [(fluoromethoxy) imino] acetyl] amino] -8-oxo-, monohydrochloride, (6R,7R) -
(9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as described by E or Z.




● HCl

RN 650590-47-9 HCAPLUS

CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,
3-[(E)-[[[[(trans-4-(aminomethyl)cyclohexyl)methyl]amino]iminomethyl]methylhydrazono]methyl]-7-[[[(2Z)-(5-amino-1,2,4-thiadiazol-3-yl) [(fluoromethoxy) imino] acetyl] amino] -8-oxo-, monohydrochloride, (6R,7R) -
(9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




● HCl

PAGE 1-A

—NH₂

RN 650590-49-1 HCAPLUS
 CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,
 3-[(E)-[[[[(trans-4-(aminomethyl)cyclohexyl)methyl]amino]iminomethyl]methy
 lhydrazono]methyl]-7-[[[(2Z)-(5-amino-1,2,4-thiadiazol-3-
 yl)(hydroxyimino)acetyl]amino]-8-oxo-, monohydrochloride, (6R,7R)- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




● HCl

RN 650590-53-7 HCAPLUS
 CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,
 3-[(E)-[[[[(trans-4-aminocyclohexyl)amino] [(trans-4-
 aminocyclohexyl)imino]methyl]methylhydrazono]methyl]-7-[[[(2Z)-(5-amino-
 1,2,4-thiadiazol-3-yl) [(fluoromethoxy)imino]acetyl]amino]-8-oxo-,
 monohydrochloride, (6R,7R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.

PAGE 1-A



PAGE 2-A

● HCl

IT 650590-51-5

RL: RCT (Reactant); RACT (Reactant or reagent)


(preparation of acylamino(methylhydrazono)methylcephalosporin derivs. as antimicrobial agents and their intermediates)

RN 650590-51-5 HCAPLUS

CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,
 3-[(E)-[[[(trans-4-aminocyclohexyl)amino]iminomethyl]methylhydrazono]methyl]-7-[[[(2Z)-(5-amino-1,2,4-thiadiazol-3-yl)[(fluoromethoxy)imino]acetyl]amino]-8-oxo-, trihydrochloride, (6R,7R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



●3 HCl

REFERENCE COUNT:

2

THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his nofil

(FILE 'HOME' ENTERED AT 16:50:34 ON 14 JUN 2007)

FILE 'REGISTRY' ENTERED AT 16:50:41 ON 14 JUN 2007

L1 STR
L2 5 SEA SSS SAM L1
L3 105 SEA SSS FUL L1

FILE 'HCAPLUS' ENTERED AT 16:55:10 ON 14 JUN 2007

L4 3 SEA ABB=ON PLU=ON L3

FILE 'REGISTRY' ENTERED AT 16:55:24 ON 14 JUN 2007

FILE 'BEILSTEIN' ENTERED AT 16:56:05 ON 14 JUN 2007

L5 0 SEA SSS FUL L1

FILE 'MARPAT' ENTERED AT 16:56:21 ON 14 JUN 2007

L6 0 SEA SSS SAM L1
L7 2 SEA SSS FUL L1
L8 0 SEA ABB=ON PLU=ON L7 NOT L4

FILE 'HCAPLUS' ENTERED AT 16:56:38 ON 14 JUN 2007

D QUE L4
D L4 IBIB ABS HITSTR TOT